Diabetic nephropathy. Type 2 diabetes mellitus with diabetic nephropathy
Conditions
Interventions
Intervention 1: Intervention group: diabetic nephropathic patients that given Sevelamer capsule 800 mg 3 times daily for two months before meal. Intervention 2: Control group: Diabetic nephropathic
Sponsors
Shahre-kord University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age over 18 years. Informed patient satisfaction diabetic nephropathy
Exclusion criteria
Exclusion criteria: Recently received treatment of hyperphosphatemia Have hypophosphatemia or hypercalcemia Pregnancy Known liver disease or active peptic ulcer5 Carbamazepine consumption
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BS. Timepoint: Before the beginning of study and two month after using the sevelamer and placebo. Method of measurement: Biochemical assay using BTand optical absorption teqniqus and centrifugation of serum by sampler.;Inflamatory factors(ESR,CRP). Timepoint: Before the beginning of study and two month after using the sevelamer and placebo. Method of measurement: quantitative qualitative.;HBA1C. Timepoint: Before the beginning of study and two month after using the sevelamer and placebo. Method of measurement: Using the optical absorption method, we first use a kind of solution that binds to the glycosylated hemoglobin and produced color then we should mesure colored HB.;Inflamatory factor(ICAM,VCAM). Timepoint: Before the beginning of study and two month after using the sevelamer and placebo. Method of measurement: Elisa(measurement the serum level of Antibody). | — |
Secondary
| Measure | Time frame |
|---|---|
| Degree of systemic inflamation. Timepoint: Befour study and two month after using the drugs. Method of measurement: Quantitative rate of Inflamatory Factor. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShadi Botshekan
Shahre-kord University of Medical Sciences
Outcome results
None listed